Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Welcome Hou-trader
Awesome verification. 290 million float. That is outstanding.
MILV trading strong right now. Lot of buying on the ASK the last 2 days. Anticipation is growing
Your showing your age Gregg. I believe even Vinny Barbarino could see the value in MILV.
Good morning Gregg and all MILVers
Thank you noodle.
Jan is still trying.
Drugmanrx. How did you find out what the initials stood for or is that an educated guess. I am just curious
Who changed the name on ihub? Good job
Hmmm. Lol is that it?? MILV will be rockin for quite some time
Lol. I still got mine but may add Monday
The release of information is just now starting. This is fantastic
Very exciting news coming out of Clark County NV. Our little MILV is about to become a big boy. Hell yeah!
Decent volume and holding steady. A little more consoladation and we should see higher levels. Looking really good.
290 float. AUDITED financials for 10 years soon. RM into Biotech. What else could you ask for??
This is good churning. I did grab 60k more this morning. And will continue to do so
Good morning MILV board. We definenitly have a special stock here.
Ive bought at .0034. And .005 and .007 and .009 and .01. It seems to be working well for me
290 mil float. Basically locked up. Filings with huge implications to be dropped soon. Got MILV? Whats not to love here
You must remember. These will be 11 years of AUDITED filings. The real deal guys.
When the filing drops, I will probably need to change my underwear.
You will be adding with others my friend. I cant have enough MILV
MILV anyone that has read the blog you supplied has to be impressed with what is going on with MILV and the RM company CCA LLC. This is truly an amazing opportunity for investors to score a huge gainer.
Glad to see tbe MILVers out and about tonight. You all must be ready for tomorrow!! I know I am
MILV All the DD done on the RM company CCA LLC is incredible. Brain trauma recovery. Brain deasese reversal. Liver protection. Patents and contract with U of Penn. MILV will be a huge biotech player
I see 2 to 3 cents happeing very quickly. We are rapidly buying up the float. Then we get filings and current. Then a nuclear ecplosion in the price
MILV is truly the best stock opportunity I have ever seen. The DD is mind blowing. I continue to buy
MILV Here is patent info.
THis could be massive what $MILV is bringing out
"With the introduction of that Vitamin E Phosphate compound to the liposome, it will reduce oxidative processes (which are destructive to the live) and strengthen liver cells.
So yes... "
Making the liver bullet proof!
Here is the patent text in detail
https://ccabiotech.blogspot.com/p/patent.html
MILV biotech RM. Unreal stuff
What's being transferred from University of Pennsylvania to MILV.
Per SEC filings
CCA and the University of Pennsylvania ("PENN") and the Children's Hospital of Philadelphia ("Children's Hospital") are engaged in a co-development alliance which is combining CCA's NPC technology with other PENN and Children's Hospital technologies to co-develop technologies to be jointly owned by CCA, PENN and Children's Hospital, including compounds to treat, and to a certain extent, prevent traumatic brain injury. This alliance also entails development involving dendrites, neurodevelopment, bone morphogenetic proteins, glutamate excitotoxicity, neural regeneration, injury-induced altered brain excitability, circuit rearrangement and synaptic function, including the development of pharmaceuticals."
CCA owns a versatile and widely-applicable biotechnology asset base. Its Nanoscale Particle Complex (“NPC”) technology represents, in the opinion of CCA's management, the leading edge of phospholipid-based nano-encapsulation delivery systems (less than 100 nanometers in diameter; mean diameter of 40 nanometers in current liquid product samples with the capability to engineer significantly smaller nanocarrier particles) that create instant delivery of payloads into the bloodstream, beginning through the membranes of the mouth. Encapsulated actives are protected from destruction in the highly acidic environment of the stomach until they reach the small intestine, providing for much greater absorption of payloads. The instant delivery aspect (an Oral IV) provides the consumer with instant gratification and effect upon consumption of the product containing the NPC technology. The NPC technology also incorporates a potent active ingredient that stimulates repair of damaged cell tissue known as "cell armor".
The NPC technology is constructed using ingredients that are biodegradable and are GRAS (generally recognized as safe) by the U.S. Food and Drug Administration. This technology platform makes feasible a broad range of close-to-the-market applications, including beverages, foods, and nutraceuticals which do not require additional regulatory review and can be brought to market rapidly. CCA believes that longer-term its NPC technology also creates the basis for a variety of pharmaceuticals. For example, CCA believes that its technology may be included in anti-cancer/general immunity modular pharmaceutical products and other pharmaceuticals (including oral, intra-nasal, and sublingual products (such as vaccines, anti-inflammatory products, analgesics, and anti-dementia, hepatic detoxification, and cardiovascular products) and topical products (such as anti-inflammatory products, analgesics, anti-infective agents (bacterial, viral and fungal) basal cell treatments and vaccines, and melanoma treatments and vaccines)).
With respect to the beverage application of CCA's NPC technology, CCA's rehydration preparation (hydrus rehydration concentrate) acts as an “Oral IV” and begins to work instantly, during a competitive event. CCA's strategy is to not only change the focus from consumption to absorption/full uptake, but to provide an Oral IV to the consumer. CCA has gained the validation of the effect of the first embodiment of the NPC technology by top world athletes who have access to a multitude of products from around the world.
The mean diameter of the nanoparticles contained in CCA's hydrus rehydration concentrate products is 44 nanometers. By comparison, the thickness of a sheet of paper is 100,000 nanometers, and the thickness of a human hair is 80,000 nanometers. Nanoparticles become invisible to the human eye at approximately 130 nanometers. CCA believes that its hydrus product is positioned as the "complete rehydration" product/solution.
CCA believes that one of the key attributes of the NPC technology that distinguishes it from all other “delivery systems” is its great utility concerning the manufacturing process. CCA can produce extremely high volumes of material/concentrate containing its loaded nanoparticles at a few cents per liter, providing a competitive advantage. Currently, CCA can manufacture internally the type of major volume of these loaded nanoparticles which would support significant launches and supply of products into the major retail chain networks throughout North America and on a global basis.
MILV hit a penny Friday before pullback to .009. The rise in share price should continue leading up to the filings. When MILV becomes current and the RM is finalized, we will be in orbit
MILV biotech RM. Unreal stuff
What's being transferred from University of Pennsylvania to MILV.
Per SEC filings
CCA and the University of Pennsylvania ("PENN") and the Children's Hospital of Philadelphia ("Children's Hospital") are engaged in a co-development alliance which is combining CCA's NPC technology with other PENN and Children's Hospital technologies to co-develop technologies to be jointly owned by CCA, PENN and Children's Hospital, including compounds to treat, and to a certain extent, prevent traumatic brain injury. This alliance also entails development involving dendrites, neurodevelopment, bone morphogenetic proteins, glutamate excitotoxicity, neural regeneration, injury-induced altered brain excitability, circuit rearrangement and synaptic function, including the development of pharmaceuticals."
CCA owns a versatile and widely-applicable biotechnology asset base. Its Nanoscale Particle Complex (“NPC”) technology represents, in the opinion of CCA's management, the leading edge of phospholipid-based nano-encapsulation delivery systems (less than 100 nanometers in diameter; mean diameter of 40 nanometers in current liquid product samples with the capability to engineer significantly smaller nanocarrier particles) that create instant delivery of payloads into the bloodstream, beginning through the membranes of the mouth. Encapsulated actives are protected from destruction in the highly acidic environment of the stomach until they reach the small intestine, providing for much greater absorption of payloads. The instant delivery aspect (an Oral IV) provides the consumer with instant gratification and effect upon consumption of the product containing the NPC technology. The NPC technology also incorporates a potent active ingredient that stimulates repair of damaged cell tissue known as "cell armor".
The NPC technology is constructed using ingredients that are biodegradable and are GRAS (generally recognized as safe) by the U.S. Food and Drug Administration. This technology platform makes feasible a broad range of close-to-the-market applications, including beverages, foods, and nutraceuticals which do not require additional regulatory review and can be brought to market rapidly. CCA believes that longer-term its NPC technology also creates the basis for a variety of pharmaceuticals. For example, CCA believes that its technology may be included in anti-cancer/general immunity modular pharmaceutical products and other pharmaceuticals (including oral, intra-nasal, and sublingual products (such as vaccines, anti-inflammatory products, analgesics, and anti-dementia, hepatic detoxification, and cardiovascular products) and topical products (such as anti-inflammatory products, analgesics, anti-infective agents (bacterial, viral and fungal) basal cell treatments and vaccines, and melanoma treatments and vaccines)).
With respect to the beverage application of CCA's NPC technology, CCA's rehydration preparation (hydrus rehydration concentrate) acts as an “Oral IV” and begins to work instantly, during a competitive event. CCA's strategy is to not only change the focus from consumption to absorption/full uptake, but to provide an Oral IV to the consumer. CCA has gained the validation of the effect of the first embodiment of the NPC technology by top world athletes who have access to a multitude of products from around the world.
The mean diameter of the nanoparticles contained in CCA's hydrus rehydration concentrate products is 44 nanometers. By comparison, the thickness of a sheet of paper is 100,000 nanometers, and the thickness of a human hair is 80,000 nanometers. Nanoparticles become invisible to the human eye at approximately 130 nanometers. CCA believes that its hydrus product is positioned as the "complete rehydration" product/solution.
CCA believes that one of the key attributes of the NPC technology that distinguishes it from all other “delivery systems” is its great utility concerning the manufacturing process. CCA can produce extremely high volumes of material/concentrate containing its loaded nanoparticles at a few cents per liter, providing a competitive advantage. Currently, CCA can manufacture internally the type of major volume of these loaded nanoparticles which would support significant launches and supply of products into the major retail chain networks throughout North America and on a global basis.
MILV weekly update. Hit a penny on Friday. Found out the merging company, CCA LLC has a patent for liver protection. Which could be put in a drink. Which would allow you to take drugs which destroy your liver and make them much safer for you liver. Mind boggling stuff being done at CCA LLC and the U of Pennsylvania. The sky is the limit with MILV
MILV hit a penny Friday before pullback to .009. The rise in share price should continue leading up to the filings. When MILV becomes current and the RM is finalized, we will be in orbit
But the Ibox needs a little work!!!! Lol. You could fill up 10 I boxes with all the DD you have on MILV
Hey Ecomike. MILV. The more I find out about the company CCA and the players involved, the happier I am with my investment here. Looks fantastic
Gregg. Are you back in the Sunshine state? Have a great weekend
Your welcome. I feel the same as you about MILV and the great people on this board who have done hundreds, if not thousands of man hours of research on MILV.
Stacy. There is currently 290 million shares in the float with MILV. Float is tradable amont of shares available to the public. What is happening with MILV is that the majority of shares are being bought by people like me. And that type of person is holding long term. Not flipping for 50% or 100% profits, but holding for 1000% and 5000%. So when the float gets bought up by people holding long term, its called locking up the float which makes shares difficult to obtain without pushing the share price higher faster. Its a great thing.
Theres your 30 Van
Good morning Jake.
Boilerroom. See you are in FERL? I got a nice stash there as well. We will see what happens